# Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)

Study · id `cardio:ct-nct05632445` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05632445](<https://clinicaltrials.gov/study/NCT05632445>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05632445

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT05632445. Randomized; single masking; primary purpose diagnostic. Start 2019-05-01 (actual); primary completion 2019-06-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT05632445, source copy `cardio:ctgov-nct05632445-2022-11-30`, retrieved 2026-10-26)
- Started: 2019-05-01 (actual) (ClinicalTrials.gov record NCT05632445, source copy `cardio:ctgov-nct05632445-2022-11-30`, retrieved 2026-10-26)
- Primary completion: 2019-06-12 (actual) (ClinicalTrials.gov record NCT05632445, source copy `cardio:ctgov-nct05632445-2022-11-30`, retrieved 2026-10-26)
- Completion: 2022-10-30 (actual) (ClinicalTrials.gov record NCT05632445, source copy `cardio:ctgov-nct05632445-2022-11-30`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT05632445, source copy `cardio:ctgov-nct05632445-2022-11-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05632445-2022-11-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA)
- Acronym: ADALA
- Condition: Left Atrial Appendage Occlusion
- Intervention (Drug): Apixaban vs. DAPT
- Lead sponsor: DR. XAVIER FREIXA
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: The ADALA Randomized Clinical Trial (`cardio:pubmed-39110427`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c2256a2b85b5744ca214c856b6980bf3e2f4c7206e9efac997f33bfacf397bd5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
